Storage and handling
STORAGE: Keep package closed. Store at room temperature away from heat or direct sunlight.
STORAGE: Keep package closed. Store at room temperature away from heat or direct sunlight.
PURINA®
PRO PLAN®
FOCUS
Hairball Remedy
Specially formulated to help prevent and eliminate hairballs in a tender chew.
ACTIVE INGREDIENT: Each 1 g piece contains 90 mg of petrolatum.
INGREDIENTS: Chicken, wheat flour, soy flour, water, petrolatum, animal digest, dried corn syrup, wheat gluten, chicken by-product meal, natural and artificial flavors, dried whey, phosphoric acid, dried cheese powder, glycerin, brewers dried yeast, salt, lecithin, sorbic acid (a preservative), calcium propionate (a preservative), added color, BHA (a preservative), Yellow 5, citric acid.
A-4793
DIRECTIONS FOR USE: Do not feed to cats under six months of age. Feed recommended amount all at one time.
TO HELP ELIMINATE HAIRBALLS IN ADULT CATS: Feed 3-6 pieces daily until the signs disappear.
TO HELP PREVENT HAIRBALLS IN ADULT CATS: Feed 3-6 pieces once or twice per week.
WARNING: Use only as directed. Should vomiting persist, consult a veterinarian. Do not administer to cats less than six months of age. Keep this and all other medication out of the reach of children and pets.
Remember that this product is not a substitute for a balanced meal. A proper diet of a complete and balanced food, fresh water in a clean container, exercise, and regular veterinary visits are all necessary to keep your cat in good health.
STORAGE: Keep package closed. Store at room temperature away from heat or direct sunlight.
MANUFACTURED BY: Nestlé Purina
PetCare Company,
St. Louis, MO 63164 USA
All trademarks are owned
by Société des Produits
Nestlé S.A.
Printed in U.S.A.
Purina.com
1-800-PROPLAN
(1-800-776-7526)
Monday - Friday, 7am - 7pm, CT.
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| petrolatum | ACTIVE INGREDIENT | 4T6H12BN9U | 1 | |
| petrolatum | ACTIVE MOIETY | 4T6H12BN9U | 1 | |
| butylated hydroxyanisole | INACTIVE INGREDIENT | REK4960K2U | 1 | |
| chicken | INACTIVE INGREDIENT | 0X8Q245Y7B | 1 | |
| citric acid monohydrate | INACTIVE INGREDIENT | 2968PHW8QP | 1 | |
| corn syrup | INACTIVE INGREDIENT | 9G5L16BK6N | 1 | |
| glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| lecithin, soybean | INACTIVE INGREDIENT | 1DI56QDM62 | 1 | |
| phosphoric acid | INACTIVE INGREDIENT | E4GA8884NN | 1 | |
| propionic acid | INACTIVE INGREDIENT | JHU490RVYR | 1 | |
| saccharomyces cerevisiae | INACTIVE INGREDIENT | 978D8U419H | 1 | |
| sodium chloride | INACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| sorbic acid | INACTIVE INGREDIENT | X045WJ989B | 1 | |
| soybean | INACTIVE INGREDIENT | L7HT8F1ZOD | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 | |
| wheat | INACTIVE INGREDIENT | 4J2I0SN84Y | 1 | |
| wheat gluten | INACTIVE INGREDIENT | 1534K8653J | 1 | |
| whey | INACTIVE INGREDIENT | 8617Z5FMF6 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 10452-5375 | 10452-5375-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| petrolatum | 4T6H12BN9U | ACTIB |
| chicken | 0X8Q245Y7B | IACT |
| wheat | 4J2I0SN84Y | IACT |
| soybean | L7HT8F1ZOD | IACT |
| water | 059QF0KO0R | IACT |
| corn syrup | 9G5L16BK6N | IACT |
| wheat gluten | 1534K8653J | IACT |
| whey | 8617Z5FMF6 | IACT |
| phosphoric acid | E4GA8884NN | IACT |
| glycerin | PDC6A3C0OX | IACT |
| saccharomyces cerevisiae | 978D8U419H | IACT |
| sodium chloride | 451W47IQ8X | IACT |
| lecithin, soybean | 1DI56QDM62 | IACT |
| sorbic acid | X045WJ989B | IACT |
| propionic acid | JHU490RVYR | IACT |
| butylated hydroxyanisole | REK4960K2U | IACT |
| citric acid monohydrate | 2968PHW8QP | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAPLEURAL | 226 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / INTRA-ARTICULAR | ADJ PH | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | CREAM / TOPICAL | 13 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / OPHTHALMIC | 55 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRA-ARTERIAL | 1.35 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LIQUID / RESPIRATORY (INHALATION) | 0.13 %w/w | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / OPHTHALMIC | 10 mg | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 6 mg | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | TABLET, EXTENDED RELEASE / ORAL | 0.19 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / EPIDURAL | 3535 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | PASTE / ORAL | 3822 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SPRAY / NASAL | 30 mg | ||
| butylated hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | TABLET, ORALLY DISINTEGRATING / ORAL | 2 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, FILM COATED / ORAL | 42 mg | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | SOLUTION/ DROPS / OPHTHALMIC | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBCUTANEOUS | 1486 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INFILTRATION | 648 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 608 mg | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | ADJ PH | ||
| glycerin | GLYCERIN | PDC6A3C0OX | CAPSULE / ORAL | 3487 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CAPSULE, EXTENDED RELEASE / ORAL | 101 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / SUBCUTANEOUS | 0.86 %w/v | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION/ DROPS / ORAL | 19 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / SUBCUTANEOUS | 28 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / SUBMUCOSAL | 17 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | ELIXIR / ORAL | 100 mg/5ml | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / PERINEURAL | 648 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | TABLET, FILM COATED / ORAL | 1.55 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | ELIXIR / ORAL | 5621 mg | ||
| lecithin, soybean | SOYBEAN LECITHIN | 1DI56QDM62 | TABLET, FILM COATED / ORAL | 0.33 mg | ||
| butylated hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | GRANULE, FOR SUSPENSION / ORAL | NA | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / SOFT TISSUE | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRACARDIAC | 70 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INHALANT / RESPIRATORY (INHALATION) | 3 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRA-ARTERIAL | 278 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER / ORAL | 840 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EFFERVESCENT / ORAL | 460 mg | ||
| butylated hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | CONCENTRATE / ORAL | 0.08 mg/1ml | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR | 0.86 %w/v | ||
| butylated hydroxyanisole | BUTYLATED HYDROXYANISOLE | REK4960K2U | CAPSULE / ORAL | 4 mg | ||
| corn syrup | CORN SYRUP | 9G5L16BK6N | TROCHE / BUCCAL | NA | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / RECTAL | 7 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INFILTRATION | 3535 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 360 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / IONTOPHORESIS | 0.6 %w/v | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYRUP / ORAL | 722 mg/5ml | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | PASTE, DENTIFRICE / DENTAL | ADJ PH | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS | NA | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SUSPENSION / ORAL | 840 mg | ||
| corn syrup | CORN SYRUP | 9G5L16BK6N | TABLET / ORAL | 14.07 mg | ||
| phosphoric acid | PHOSPHORIC ACID | E4GA8884NN | TABLET, ORALLY DISINTEGRATING / ORAL | 4 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRALESIONAL | 0.9 %w/v | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| citric acid monohydrate | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SPRAY / NASAL | 9 mg | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / NASAL | 7.4 mg/1ml | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | POWDER / TOPICAL | NA | ||
| sodium chloride | SODIUM CHLORIDE | 451W47IQ8X | GEL / OPHTHALMIC | 0.9 %w/v |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Adverse event summaries are temporarily unavailable. Other product information remains available.